INTRODUCTION {#s1}
============

The increasing incidence of esophagogastric junction adenocarcinoma (EGJA) was observed worldwide \[[@R1]--[@R3]\] and was considered to have different etiology and risk factor compared with distal gastric carcinoma (GC) \[[@R4]\]. EGJA remains poor prognosis \[[@R5]\] and is a common public health problem. The vital risk factors contributing to the development of EGJA are obesity, gastro-esophageal reflux disease, smoking, foods preserved by salting and low intake of fruits and vegetables *et al* \[[@R6], [@R7]\]. However, these observed risk factors could not interpret the overall susceptibility to EGJA. Recently, more and more epidemiologic studies suggested that individual's genetic factor might influence the pathogenesis of EGJA.

Accumulating evidences indicate that folate insufficiency may increase the susceptibility of multiple malignancies \[[@R8], [@R9]\]. In humans, the majority of methyl groups may be presented by folic acid for endocellular methylation reactions and DNA de novo deoxynucleoside synthesis. During DNA synthesis, lack of folate can cause uracil misincorporation and then affect the stability of DNA \[[@R10]\]. In folate metabolism and DNA synthesis, methylenetetrahydrofolate reductase (MTHFR) is an important enzyme which catalyzes the revivification of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. And 5-methyltetrahydrofolate is a main circulating and existing form of folate and is the methyl donor for DNA methylation and remethylation procedure of homocysteine to methionine. Based on the important role of participation in both DNA synthesis and methylation, any variant of *MTHFR* gene may involve in the carcinogenesis.

Human MTHFR is composed of 656 amino acids. *MTHFR* gene is located on the short arm of Chromosome 1. The human *MTHFR* gene is very polymorphic (<http://www.ncbi.nlm.nih.gov/SNP>) and a number of loci have been established, such as rs1537514, rs3753584, rs9651118, rs1537516, rs4845882, rs1801131, rs1801133, rs2066462, rs4846048 and rs3737967 polymorphisms, etc. Interestingly, many previous case-control studies demonstrated that *MTHFR* polymorphisms were correlated with the risk of multiple human malignancies \[e.g., esophageal squamous cell carcinoma (ESCC) \[[@R11]\], gastric cardia adenocarcinoma (GCA) \[[@R12]\], cervicalcancer \[[@R13]\], breast cancer \[[@R14], [@R15]\] and childhood acute lymphoblastic leukemia \[[@R16]\] *et al*\]. Thus, the single nucleotide polymorphisms (SNPs) in *MTHFR* genes on EGJA risk attracted our interest. Exploring the potential association of *MTHFR* SNPs with EGJA susceptibility may be conducive to the prevention and personalized diagnosis. In this study, we selected *MTHFR* tagging SNPs (rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C) and performed a case-control study to evaluate the effect of *MTHFR* genotypes for EGJA risk.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

A total of 1,063 sporadic patients with EGJA and 1,677 normal controls were recruited. Of the EJGA patients, 759 were male and 304 were female, with a mean age (± standard deviation) of 64.19 ±8.63 years. The normal controls comprised of 1,194 males and 483 females with a mean age of 63.91 ±10.22 years. The demographics (age and sex) was well matched (*P* = 0.165 and *P* = 0.909, respectively; Table [1](#T1){ref-type="table"}). Of the smoking and alcohol consumption, a significant difference was observed between EGJA patients and controls (*P* \< 0.001, Table [1](#T1){ref-type="table"}). The frequency distribution of *MTHFR* genotypes was determined after genotyping the 2,740 study subjects. For *MTHFR* rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms, success rates of genotyping were 99.01%, 99.09%, 99.05%, 99.09% and 98.98%, respectively (Table [2](#T2){ref-type="table"}). In controls, the distribution of *MTHFR* genotype frequencies accorded with Hardy--Weinberg equilibrium (HWE), except for *MTHFR* rs4846048 A\>G polymorphism (Table [2](#T2){ref-type="table"}).

###### Distribution of selected demographic variables and risk factors in EGJA cases and controls

  Variable         Overall Cases (n=1,063)   Overall Controls (n=1,677)   *P* ^a^
  ---------------- ------------------------- ---------------------------- -------------
  Age (years)      64.19 ±8.63               63.91 ±10.22                 0.451
  Age (years)                                                             0.165
   \< 64           494 (46.47)               825 (49.19)                  
   ≥64             569 (53.53)               852 (50.81)                  
  Sex                                                                     0.909
   Male            759 (71.40)               1194 (71.20)                 
   Female          304 (28.60)               483 (28.80)                  
  Smoking status                                                          **\<0.001**
   Never           773 (72.72)               1323 (78.89)                 
   Ever            290 (27.28)               354 (21.11)                  
  Alcohol use                                                             **\<0.001**
   Never           908 (85.42)               1507 (89.86)                 
   Ever            155 (14.58)               170 (10.14)                  

^a^ Two-sided *χ*^2^ test and Student *t* test.

###### Primary information for *MTHFR* polymorphisms (rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C)

  Genotyped SNPs                              rs1801133 G\>A   rs3753584 T\>C   rs4845882 G\>A   rs4846048 A\>G   rs9651118 T\>C
  ------------------------------------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Chromosome                                  1                1                1                1                1
  Function                                    Missense         NearGene-5       Intron           Intron           Intron
  Chr Pos (Genome Build 36.3)                 11778965         11787173         11765754         11768839         11784801
  MAF^a^ for Chinese in database              0.439            0.093            0.198            0.105            0.382
  MAF in our controls (n = 1,677)             0.359            0.108            0.209            0.096            0.378
  *P* value for HWE^b^ test in our controls   0.679            0.691            0.972            0.014            0.270
  Genotyping method                           SNPscan          SNPscan          SNPscan          SNPscan          SNPscan
  \% Genotyping value                         99.01%           99.09%           99.05%           99.09%           98.98%

^a^MAF: minor allele frequency.

^b^HWE: Hardy--Weinberg equilibrium.

Association of *MTHFR* rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms with EGJA {#s2_2}
--------------------------------------------------------------------------------------------------------------------------------

The genotypes of *MTHFR* rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms are presented in Table [3](#T3){ref-type="table"}. For *MTHFR* rs1801133 G\>A polymorphism, the risk of developing EGJA was significant in three genetic models \[AA *vs.* GG: crude odds ratio (OR) = 1.50, 95% confidence interval (CI): 1.19--1.90, *P* = 0.001; GA/AA *vs.* GG: crude OR = 1.27, 95% CI: 1.08--1.49, *P* = 0.004 and AA *vs.* GA/GG: crude OR = 1.45, 95% CI: 1.17--1.80, *P* = 0.001; Table [3](#T3){ref-type="table"}\]. Adjustment for age, sex, smoking and drinking, the similar results were also found (AA *vs.* GG: adjusted OR = 1.47, 95% CI: 1.16--1.86, *P* = 0.001; GA/AA *vs.* GG: adjusted OR = 1.25, 95% CI: 1.06--1.47, *P* = 0.007 amd AA *vs.* GA/GG: adjusted OR = 1.43, 95% CI: 1.15--1.77, *P* = 0.001; Table [3](#T3){ref-type="table"}). For *MTHFR* rs4845882 G\>A polymorphism, the decreased risk of EGJA was found in two genetic models (AA *vs.* GG: crude OR = 0.47, 95% CI: 0.29--0.75, *P* = 0.002 and AA *vs.* GA/GG: crude OR = 0.50, 95% CI: 0.31--0.80, *P* = 0.004; Table [3](#T3){ref-type="table"}). Adjustment for age, sex, smoking and drinking, the results were not materially changed (AA *vs.* GG: adjusted OR = 0.47, 95% CI: 0.29--0.76, *P* = 0.002 and AA *vs.* GA/GG: adjusted OR = 0.50, 95% CI: 0.31--0.81, *P* = 0.005; Table [3](#T3){ref-type="table"}). In addition, these associations were still significant after a Bonferroni correction for multiple comparisons.

###### Logistic regression analyses of associations between *MTHFR* rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms and the risk of EGJA

  ------------------------------------------------------------------------------------------------------------------------------------------
  Genotype                 Cases\      Controls\   Crude OR\   *P*     Adjusted OR ^a^\       *P*                                
                           (n=1,063)   (n=1,677)   (95%CI)             (95%CI)                                                   
  ------------------------ ----------- ----------- ----------- ------- ---------------------- ----------- ---------------------- -----------
  *MTHFR* rs1801133 G\>A                                                                                                         

  GG                       367         35.29       683         40.82   1.00                               1.00                   

  GA                       492         47.31       778         46.50   1.11 (0.94-1.32)       0.208       1.10 (0.93-1.30)       0.263

  AA                       181         17.40       212         12.67   **1.50 (1.19-1.90)**   **0.001**   **1.47 (1.16-1.86)**   **0.001**

  GA + AA                  673         64.71       990         59.18   **1.27 (1.08-1.49)**   **0.004**   **1.25 (1.06-1.47)**   **0.007**

  GG+ GA                   859         82.60       1,461       87.33   1.00                               1.00                   

  AA                       181         17.40       212         12.67   **1.45 (1.17-1.80)**   **0.001**   **1.43 (1.15-1.77)**   **0.001**

  A allele                 854         41.06       1,202       35.92                                                             

  *MTHFR* rs3753584 T\>C                                                                                                         

  TT                       855         82.13       1,330       79.45   1.00                               1.00                   

  CT                       177         17.00       326         19.47   0.83 (0.67-1.01)       0.062       0.83 (0.68-1.01)       0.067

  CC                       9           0.86        18          1.08    0.76 (0.34-1.70)       0.504       0.73 (0.32-1.63)       0.440

  CT+CC                    186         17.87       344         20.55   0.84 (0.69-1.03)       0.087       0.84 (0.69-1.03)       0.091

  TT+CT                    1032        99.14       1,656       98.92   1.00                               1.00                   

  CC                       9           0.86        18          1.08    0.80 (0.36-1.79)       0.591       0.77 (0.34-1.72)       0.516

  C allele                 195         9.37        362         10.81                                                             

  *MTHFR* rs4845882 G\>A                                                                                                         

  GG                       687         66.06       1,049       62.66   1.00                               1.00                   

  GA                       330         31.73       552         32.97   0.89 (0.75-1.05)       0.153       0.89 (0.75-1.05)       0.150

  AA                       23          2.21        73          4.36    **0.47 (0.29-0.75)**   **0.002**   **0.47 (0.29-0.76)**   **0.002**

  GA+AA                    353         33.94       625         37.34   0.86 (0.73-1.01)       0.074       0.86 (0.73-1.02)       0.075

  GG+GA                    1,017       97.79       1,601       95.64   1.00                               1.00                   

  AA                       23          2.21        73          4.36    **0.50 (0.31-0.80)**   **0.004**   **0.50 (0.31-0.81)**   **0.005**

  A allele                 376         18.08       698         20.85                                                             

  *MTHFR* rs4846048 A\>G                                                                                                         

  AA                       860         82.61       1,378       82.32   1.00                               1.00                   

  AG                       171         16.43       272         16.25   0.98 (0.80-1.21)       0.883       0.99 (0.80-1.22)       0.921

  GG                       10          0.96        24          1.43    0.65 (0.31-1.37)       0.260       0.63 (0.30-1.34)       0.230

  AG+GG                    181         17.39       296         17.68   0.98 (0.80-1.20)       0.845       0.98 (0.80-1.21)       0.870

  AA+AG                    1,031       99.04       1,650       98.57   1.00                               1.00                   

  GG                       10          0.96        24          1.43    0.67 (0.32-1.40)       0.284       0.65 (0.31-1.36)       0.250

  G allele                 191         9.17        320         9.56                                                              

  *MTHFR* rs9651118 T\>C                                                                                                         

  TT                       423         40.75       638         38.11   1.00                               1.00                   

  TC                       486         46.82       808         48.27   0.86 (0.73-1.02)       0.075       0.87 (0.74-1.03)       0.105

  CC                       129         12.43       228         13.62   0.81 (0.63-1.04)       0.094       0.83 (0.65-1.07)       0.150

  TC+CC                    615         59.25       1,036       61.89   0.90 (0.76-1.05)       0.171       0.91 (0.78-1.07)       0.260

  TT+TC                    909         87.57       1,446       86.38   1.00                               1.00                   

  CC                       129         12.43       228         13.62   0.90 (0.71-1.13)       0.372       0.92 (0.73-1.16)       0.489

  C allele                 744         35.84       1,264       37.75                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted for age, sex, smoking and drinking status; Bold values are statistically significant (*P* \<0.05).

Association of *MTHFR* rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms with EGJA in Different Stratification Groups {#s2_3}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

In the stratified analyses by sex, age, drinking and smoking, the genotype frequencies of *MTHFR* rs1801133 G\>A polymorphism are listed in Table [4](#T4){ref-type="table"}. After adjustment by logistic regression analysis, the association of *MTHFR* rs1801133 G\>A variants with EGJA risk was evident in some subgroups \[male group: AA *vs.* GG: adjusted OR = 1.66, 95% CI 1.26--2.20, *P* \< 0.001, GA/AA *vs.* GG: adjusted OR = 1.27, 95% CI 1.05--1.53, *P* = 0.015 and AA *vs.* GA/GG: adjusted OR = 1.61, 95% CI 1.24--2.08, *P* \< 0.001; \<64 years subgroup: AA *vs.* GG: adjusted OR = 1.51, 95% CI 1.06--2.14, *P* = 0.022, GA/AA *vs.* GG: adjusted OR = 1.38, 95% CI 1.09--1.74, *P* = 0.007 and AA *vs.* GA/GG: adjusted OR = 1.39, 95% CI 1.00--1.92, *P* = 0.049; ≥64 years subgroup: AA *vs.* GG: adjusted OR = 1.42, 95% CI 1.03--1.95, *P* = 0.032 and AA *vs.* GA/GG: adjusted OR = 1.47, 95% CI 1.10--1.96, *P* = 0.010; never smoking group: AA *vs.* GG: adjusted OR = 1.43, 95% CI 1.08--1.87, *P* = 0.012, GA/AA *vs.* GG: adjusted OR = 1.32, 95% CI 1.10--1.59, *P* = 0.004 and AA *vs.* GA/GG: adjusted OR = 1.33, 95% CI 1.04--1.72, *P* = 0.026; ever smoking group: AA *vs.* GG: adjusted OR = 1.62, 95% CI 1.01--2.61, *P* = 0.046 and AA *vs.* GA/GG: adjusted OR = 1.79, 95% CI 1.15--2.76, *P* = 0.009 and never drinking group: AA *vs.* GG: adjusted OR = 1.54, 95% CI 1.20--1.98, *P* = 0.001, GA/AA *vs.* GG: adjusted OR = 1.35, 95% CI 1.13--1.60, *P* = 0.001 and AA *vs.* GA/GG: adjusted OR = 1.45, 95% CI 1.15--1.82, *P* = 0.002; Table [4](#T4){ref-type="table"})\].

###### Stratified analyses between *MTHFR* rs1801133 G\>A polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              *MTHFR* rs1801133 G\>A (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                           
  --------------------- ------------------------------------------ ------------------------------ --------- ------ -------------------- ------------------------ ------------------------ ------------------------
  Sex                                                                                                                                                                                     

  Male                  260/485                                    350/563                        135/142   1.00   1.10 (0.90-1.34);\   **1.66 (1.26-2.20);**\   **1.27 (1.05-1.53);**\   **1.61 (1.24-2.08);**\
                                                                                                                   *P*: 0.360           ***P*: \< 0.001**        ***P*: 0.015**           ***P*: \< 0.001**

  Female                107/198                                    142/215                        46/70     1.00   1.10 (0.80-1.50);\   1.03 (0.66-1.60);\       1.17 (0.86-1.59);\       1.01 (0.67-1.53);\
                                                                                                                   *P*: 0.575           *P*: 0.909               *P*: 0.311               *P*: 0.954

  Age                                                                                                                                                                                     

  \<64                  173/362                                    233/363                        76/98     1.00   1.24 (0.97-1.58);\   **1.51 (1.06-2.14);**\   **1.38 (1.09-1.74);**\   **1.39 (1.00-1.92);**\
                                                                                                                   *P*: 0.089           ***P*: 0.022**           ***P*: 0.007**           ***P*: 0.049**

  ≥64                   194/321                                    259/415                        105/114   1.00   0.97 (0.77-1.23);\   **1.42 (1.03-1.95);**\   1.12 (0.90-1.40);\       **1.47 (1.10-1.96);**\
                                                                                                                   *P*: 0.822           ***P*: 0.032**           *P*: 0.312               ***P*: 0.010**

  Smoking status                                                                                                                                                                          

  Never                 263/549                                    368/603                        123/168   1.00   1.19 (0.98-1.44);\   **1.43 (1.08-1.87);**\   **1.32 (1.10-1.59);**\   **1.33 (1.04-1.72);**\
                                                                                                                   *P*: 0.085           ***P*: 0.012**           ***P*: 0.004**           ***P*: 0.026**

  Ever                  104/134                                    124/175                        58/44     1.00   0.86 (0.61-1.22);\   **1.62 (1.01-2.61);**\   1.04 (0.75-1.45);\       **1.79 (1.15-2.76);**\
                                                                                                                   *P*: 0.396           ***P*: 0.046**           *P*: 0.805               ***P*: 0.009**

  Alcohol consumption                                                                                                                                                                     

  Never                 308/631                                    426/686                        152/187   1.00   1.19 (0.99-1.42);\   **1.54 (1.20-1.98);**\   **1.35 (1.13-1.60);**\   **1.45 (1.15-1.82);**\
                                                                                                                   *P*: 0.065           ***P*: 0.001**           ***P*: 0.001**           ***P*: 0.002**

  Ever                  59/52                                      66/92                          29/25     1.00   0.60 (0.36-1.00);\   1.10 (0.56-2.19);\       0.70 (0.43-1.13);\       1.47 (0.80-2.73);\
                                                                                                                   *P*: 0.051           *P*: 0.780               *P*: 0.138               *P*: 0.217
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ The genotyping was successful in 1063 (97.84%) EGJA cases, and 1677 (99.76%) controls for *MTHFR* rs1801133 G\>A;

^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

Table [5](#T5){ref-type="table"} summarizes the results of association between *MTHFR* rs3753584 T\>C polymorphism and EGJA risk in the stratified analysis. We found that *MTHFR* rs3753584 T\>C polymorphism was associated with the decreased risk of EGJA in \<64 years subgroup \[TC *vs.* TT: adjusted OR = 0.70, 95% CI 0.52--0.93, *P* = 0.016 and TC/CC *vs.* TT: adjusted OR = 0.73, 95% CI 0.55--0.97, *P* = 0.032 (Table [5](#T5){ref-type="table"})\].

###### Stratified analyses between *MTHFR* rs3753584 T\>C polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              *MTHFR* rs3753584 T\>C (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                        
  --------------------- ------------------------------------------ ------------------------------ ------ ------ ------------------------ -------------------- ------------------------ --------------------
  Sex                                                                                                                                                                                  

  Male                  613/950                                    126/226                        7/15   1.00   0.85 (0.67-1.08);\       0.69 (0.28-1.70);\   0.85 (0.67-1.08);\       0.72 (0.29-1.78);\
                                                                                                                *P*: 0.177               *P*: 0.415           *P*: 0.184               *P*: 0.471

  Female                242/380                                    51/100                         2/3    1.00   0.80 (0.55-1.17);\       0.61 (0.08-4.43);\   0.83 (0.57-1.20);\       0.64 (0.09-4.72);\
                                                                                                                *P*: 0.252               *P*: 0.622           *P*: 0.319               *P*: 0.663

  Age                                                                                                                                                                                  

  \<64                  398/640                                    79/177                         5/7    1.00   **0.70 (0.52-0.93);**\   0.99 (0.31-3.19);\   **0.73 (0.55-0.97);**\   1.08 (0.34-3.47);\
                                                                                                                ***P*: 0.016**           *P*: 0.987           ***P*: 0.032**           *P*: 0.899

  ≥64                   457/691                                    98/149                         4/11   1.00   0.98 (0.74-1.30);\       0.53 (0.17-1.68);\   0.97 (0.73-1.28);\       0.54 (0.17-1.71);\
                                                                                                                *P*: 0.881               *P*: 0.282           *P*: 0.813               *P*: 0.296

  Smoking status                                                                                                                                                                       

  Never                 619/1,058                                  131/249                        4/14   1.00   0.88 (0.70-1.11);\       0.47 (0.16-1.45);\   0.88 (0.70-1.11);\       0.49 (0.16-1.51);\
                                                                                                                *P*: 0.283               *P*: 0.189           *P*: 0.288               *P*: 0.216

  Ever                  236/272                                    46/77                          5/4    1.00   0.74 (0.49-1.11);\       1.22 (0.31-4.74);\   0.77 (0.52-1.15);\       1.29 (0.33-5.04);\
                                                                                                                *P*: 0.144               *P*: 0.776           *P*: 0.202               *P*: 0.711

  Alcohol consumption                                                                                                                                                                  

  Never                 729/1,190                                  152/299                        6/16   1.00   0.81 (0.65-1.00);\       0.59 (0.23-1.52);\   0.82 (0.66-1.01);\       0.63 (0.24-1.61);\
                                                                                                                *P*: 0.052               *P*: 0.273           *P*: 0.064               *P*: 0.331

  Ever                  126/140                                    25/27                          3/2    1.00   1.11 (0.60-2.06);\       1.52 (0.24-9.63);\   1.14 (0.63-2.07);\       1.49 (0.24-9.44);\
                                                                                                                *P*: 0.748               *P*: 0.657           *P*: 0.668               *P*: 0.669
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ The genotyping was successful in 1063 (97.93%) EGJA cases, and 1677 (99.82%) controls for *MTHFR* rs3753584 T\>C;

^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

The results of association between *MTHFR* rs4845882 G\>A polymorphism and EGJA risk in the stratified analyses are summarized in Table [6](#T6){ref-type="table"}. We found that *MTHFR* rs4845882 G\>A polymorphism decreased the risk of EGJA in several subgroups \[male group: AA *vs.* GG: adjusted OR = 0.47, 95% CI 0.27--0.83, *P* = 0.009 and AA *vs.* GA/GG: adjusted OR = 0.50, 95% CI 0.29--0.87, *P* = 0.014; \<64 years subgroup: AA *vs.* GG: adjusted OR = 0.41, 95% CI 0.20--0.84, *P* = 0.015 and AA *vs.* GA/GG: adjusted OR = 0.45, 95% CI 0.22--0.91, *P* = 0.027; never smoking group: AA *vs.* GG: adjusted OR = 0.37, 95% CI 0.21--0.67, *P* = 0.001 and AA *vs.* GA/GG: adjusted OR = 0.39, 95% CI 0.22--0.70, *P* = 0.002 and never drinking group: AA *vs.* GG: adjusted OR = 0.44, 95% CI 0.26--0.74, *P* = 0.002, GA/AA *vs.* GG: adjusted OR = 0.83, 95% CI 0.69--0.98, *P* = 0.032 and AA *vs.* GA/GG: adjusted OR = 0.48, 95% CI 0.29--0.80, *P* = 0.005 (Table [6](#T6){ref-type="table"})\].

###### Stratified analyses between *MTHFR* rs4845882 G\>A polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              *MTHFR* rs4845882 G\>A (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                         
  --------------------- ------------------------------------------ ------------------------------ ------- ------ -------------------- ------------------------ ------------------------ ------------------------
  Sex                                                                                                                                                                                   

  Male                  492/746                                    237/391                        17/54   1.00   0.89 (0.73-1.09);\   **0.47 (0.27-0.83);**\   0.86 (0.71-1.05);\       **0.50 (0.29-0.87);**\
                                                                                                                 *P*: 0.268           ***P*: 0.009**           *P*: 0.113               ***P*: 0.014**

  Female                195/303                                    93/161                         6/19    1.00   0.86 (0.63-1.18);\   0.43 (0.16-1.12);\       0.86 (0.63-1.17);\       0.46 (0.18-1.21);\
                                                                                                                 *P*: 0.354           *P*: 0.084               *P*: 0.330               *P*: 0.117

  Age                                                                                                                                                                                   

  \<64                  320/507                                    152/279                        10/37   1.00   0.83 (0.65-1.06);\   **0.41 (0.20-0.84);**\   0.81 (0.64-1.02);\       **0.45 (0.22-0.91);**\
                                                                                                                 *P*: 0.132           ***P*: 0.015**           *P*: 0.077               ***P*: 0.027**

  ≥64                   367/542                                    178/273                        13/36   1.00   0.94 (0.74-1.18);\   0.53 (0.28-1.01);\       0.91 (0.73-1.14);\       0.55 (0.29-1.04);\
                                                                                                                 *P*: 0.566           *P*: 0.052               *P*: 0.424               *P*: 0.068

  Smoking status                                                                                                                                                                        

  Never                 496/832                                    243/427                        14/62   1.00   0.92 (0.76-1.12);\   **0.37 (0.21-0.67);**\   0.89 (0.73-1.07);\       **0.39 (0.22-0.70);**\
                                                                                                                 *P*: 0.416           ***P*: 0.001**           *P*: 0.207               ***P*: 0.002**

  Ever                  191/217                                    87/125                         9/11    1.00   0.81 (0.58-1.14);\   0.96 (0.38-2.40);\       0.83 (0.60-1.16);\       1.04 (0.42-2.59);\
                                                                                                                 *P*: 0.220           *P*: 0.927               *P*: 0.269               *P*: 0.939

  Alcohol consumption                                                                                                                                                                   

  Never                 591/938                                    276/501                        19/66   1.00   0.85 (0.71-1.01);\   **0.44 (0.26-0.74);**\   **0.83 (0.69-0.98);**\   **0.48 (0.29-0.80);**\
                                                                                                                 *P*: 0.065           ***P*: 0.002**           ***P*: 0.032**           ***P*: 0.005**

  Ever                  96/111                                     54/51                          4/7     1.00   1.30 (0.80-2.12);\   0.85 (0.23-3.19);\       1.25 (0.78-2.02);\       0.78 (0.21-2.87);\
                                                                                                                 *P*: 0.293           *P*: 0.813               *P*: 0.355               *P*: 0.708
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ The genotyping was successful in 1063 (97.84%) EGJA cases, and 1677 (99.82%) controls for *MTHFR* rs4845882 G\>A;

^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

Table [7](#T7){ref-type="table"} lists *MTHFR* rs4846048 A\>G genotype frequencies in the stratified analysis. We found no significant difference in genotype distribution of *MTHFR* rs4846048 A\>G polymorphism among EGJA cases and non-cancer controls.

###### Stratified analyses between *MTHFR* rs4846048 A\>G polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              *MTHFR* rs4846048 A\>G (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                
  --------------------- ------------------------------------------ ------------------------------ ------ ------ -------------------- -------------------- -------------------- --------------------
  Sex                                                                                                                                                                          

  Male                  615/984                                    124/189                        7/18   1.00   1.04 (0.81-1.33);\   0.58 (0.24-1.40);\   1.02 (0.80-1.29);\   0.58 (0.24-1.41);\
                                                                                                                *P*: 0.772           *P*: 0.227           *P*: 0.904           *P*: 0.233

  Female                245/394                                    47/83                          3/6    1.00   0.88 (0.59-1.30);\   0.73 (0.18-2.96);\   0.90 (0.61-1.32);\   0.77 (0.19-3.11);\
                                                                                                                *P*: 0.522           *P*: 0.659           *P*: 0.597           *P*: 0.711

  Age                                                                                                                                                                          

  \<64                  398/677                                    78/134                         6/12   1.00   0.99 (0.73-1.34);\   0.74 (0.27-2.02);\   0.99 (0.74-1.34);\   0.76 (0.28-2.07);\
                                                                                                                *P*: 0.927           *P*: 0.562           *P*: 0.955           *P*: 0.590

  ≥64                   462/701                                    93/138                         4/12   1.00   1.00 (0.75-1.33);\   0.48 (0.15-1.51);\   0.97 (0.74-1.29);\   0.49 (0.16-1.53);\
                                                                                                                *P*: 0.981           *P*: 0.210           *P*: 0.855           *P*: 0.221

  Smoking status                                                                                                                                                               

  Never                 624/1,081                                  125/220                        5/20   1.00   0.96 (0.75-1.22);\   0.43 (0.16-1.16);\   0.94 (0.74-1.19);\   0.45 (0.17-1.19);\
                                                                                                                *P*: 0.725           *P*: 0.095           *P*: 0.611           *P*: 0.107

  Ever                  236/297                                    46/52                          5/4    1.00   1.13 (0.73-1.75);\   1.49 (0.39-5.72);\   1.17 (0.77-1.78);\   1.47 (0.38-5.66);\
                                                                                                                *P*: 0.582           *P*: 0.563           *P*: 0.473           *P*: 0.572

  Alcohol consumption                                                                                                                                                          

  Never                 736/1,236                                  145/248                        6/21   1.00   0.96 (0.77-1.20);\   0.47 (0.19-1.16);\   0.95 (0.76-1.18);\   0.48 (0.19-1.19);\
                                                                                                                *P*: 0.709           *P*: 0.101           *P*: 0.613           *P*: 0.115

  Ever                  124/142                                    26/24                          4/3    1.00   1.31 (0.70-2.46);\   1.77 (0.36-8.68);\   1.35 (0.74-2.46);\   1.70 (0.35-8.32);\
                                                                                                                *P*: 0.406           *P*: 0.483           *P*: 0.323           *P*: 0.512
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ The genotyping was successful in 1063 (97.93%) EGJA cases, and 1677 (99.82%) controls for *MTHFR* rs4846048 A\>G;

^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

The results of relationship between *MTHFR* rs9651118 T\>C polymorphism and EGJA risk in the stratified analyses are summarized in Table [8](#T8){ref-type="table"}. We found that *MTHFR* rs9651118 T\>C polymorphism was associated with the decreased risk of EGJA in \<64 years subgroup \[TC *vs.* TT: adjusted OR = 0.78, 95% CI 0.61--0.99, *P* = 0.040 (Table [8](#T8){ref-type="table"})\].

###### Stratified analyses between *MTHFR* rs9651118 T\>C polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              *MTHFR* rs9651118 T\>C (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                       
  --------------------- ------------------------------------------ ------------------------------ --------- ------ ------------------------ -------------------- -------------------- --------------------
  Sex                                                                                                                                                                                 

  Male                  309/447                                    339/574                        95/170    1.00   0.82 (0.68-1.00);\       0.80 (0.60-1.07);\   0.86 (0.71-1.04);\   0.91 (0.69-1.19);\
                                                                                                                   *P*: 0.054               *P*: 0.134           *P*: 0.109           *P*: 0.492

  Female                114/191                                    147/234                        34/58     1.00   1.03 (0.76-1.40);\       0.99 (0.61-1.61);\   1.11 (0.82-1.50);\   1.01 (0.64-1.60);\
                                                                                                                   *P*: 0.857               *P*: 0.970           *P*: 0.501           *P*: 0.956

  Age                                                                                                                                                                                 

  \<64                  190/288                                    231/424                        59/111    1.00   **0.78 (0.61-0.99);**\   0.80 (0.55-1.15);\   0.83 (0.66-1.05);\   0.95 (0.68-1.34);\
                                                                                                                   ***P*: 0.040**           *P*: 0.225           *P*: 0.128           *P*: 0.767

  ≥64                   233/350                                    255/384                        70/117    1.00   0.96 (0.76-1.21);\       0.89 (0.63-1.25);\   0.99 (0.80-1.23);\   0.93 (0.68-1.28);\
                                                                                                                   *P*: 0.728               *P*: 0.502           *P*: 0.914           *P*: 0.651

  Smoking status                                                                                                                                                                      

  Never                 299/499                                    357/636                        95/186    1.00   0.88 (0.73-1.06);\       0.80 (0.60-1.06);\   0.92 (0.77-1.11);\   0.89 (0.68-1.16);\
                                                                                                                   *P*: 0.182               *P*: 0.126           *P*: 0.380           *P*: 0.374

  Ever                  124/140                                    129/173                        34/43     1.00   0.83 (0.59-1.16);\       0.95 (0.56-1.59);\   0.87 (0.63-1.19);\   1.05 (0.64-1.72);\
                                                                                                                   *P*: 0.270               *P*: 0.835           *P*: 0.378           *P*: 0.843

  Alcohol consumption                                                                                                                                                                 

  Never                 357/564                                    415/728                        113/213   1.00   0.86 (0.72-1.03);\       0.80 (0.62-1.04);\   0.90 (0.76-1.06);\   0.89 (0.70-1.14);\
                                                                                                                   *P*: 0.092               *P*: 0.096           *P*: 0.214           *P*: 0.369

  Ever                  66/74                                      71/80                          16/15     1.00   0.93 (0.57-1.49);\       1.12 (0.50-2.51);\   0.97 (0.61-1.54);\   1.17 (0.54-2.53);\
                                                                                                                   *P*: 0.750               *P*: 0.783           *P*: 0.907           *P*: 0.686
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ The genotyping was successful in 1063 (97.65%) EGJA cases, and 1677 (99.82%) controls for *MTHFR* rs9651118 T\>C;

^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

SNP haplotypes {#s2_4}
--------------

We used a SHESIS software (<http://analysis.bio-x.cn/myAnalysis.php>) \[[@R17]\] to construct haplotypes of *MTHFR* gene (Table [9](#T9){ref-type="table"}). Finally, five *MTHFR* haplotypes were identified. When *MTHFR* A~rs1801133~T~rs3753584~G~rs4845882~A~rs4846048~T~rs9651118~ haplotype was used as reference, we found that *MTHFR* G~rs1801133~T~rs3753584~G~rs4845882~A~rs4846048~C~rs9651118~, G~rs1801133~C~rs3753584~A~rs4845882~A~rs4846048~T~rs9651118~ and G~rs1801133~T~rs3753584~A~rs4845882~G~rs4846048~T~rs9651118~ haplotypes significantly decreased the risk of EGJA (*P* = 0.002, *P* \< 0.001 and *P* = 0.038, respectively, Table [9](#T9){ref-type="table"}).

###### *MTHFR* haplotype frequencies (%) in patients and controls and risk of esophagogastric junction adenocarcinom

  Haplotypes                                                     Case (n=2,126)   Control (n=3,354)   Crude OR (95% CI)   *P*                            
  -------------------------------------------------------------- ---------------- ------------------- ------------------- ------- ---------------------- -------------
  A~rs1801133~T~rs3753584~G~rs4845882~A~rs4846048~T~rs9651118~   814              39.36               1169                34.92   1.00                   
  G~rs1801133~T~rs3753584~G~rs4845882~A~rs4846048~C~rs9651118~   708              34.24               1244                37.16   **0.82 (0.72-0.93)**   **0.002**
  G~rs1801133~C~rs3753584~A~rs4845882~A~rs4846048~T~rs9651118~   171              8.27                335                 10.01   **0.69 (0.56-0.85)**   **\<0.001**
  G~rs1801133~T~rs3753584~A~rs4845882~G~rs4846048~T~rs9651118~   173              8.37                309                 9.23    **0.80 (0.65-0.99)**   **0.038**
  G~rs1801133~T~rs3753584~G~rs4845882~A~rs4846048~T~rs9651118~   130              6.29                206                 6.15    0.91 (0.72-1.15)       0.416
  Others                                                         72               3.48                85                  2.54    1.22 (0.88-1.69)       0.239

DISCUSSION {#s3}
==========

Incidence of EGJA has increased over the past two decades \[[@R18], [@R19]\]. Many studies demonstrated that the morbidity of EGJA was increased in Asian countries, such as China, Korea and Japan \[[@R19]--[@R21]\]. However, the etiology of EGJA remains unknown. In this study, we explored the association between *MTHFR* rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms and EGJA risk in Eastern Chinese Han population. We found that *MTHFR* rs1801133 G\>A might be associated with the increased risk of EGJA. Meanwhile, *MTHFR* rs3753584 T\>C, rs4845882 G\>A and rs9651118 T\>C polymorphisms decreased the risk of EGJA.

*MTHFR* gene lies in 1p36.3 and contains 11 exons with a length of about 1980 bp. In exon 4, a G to A variant at nucleotide 677 locus (rs1801133 G\>A) directly leads to valine substitution for alanine, which is relevant to a reduction of MTHFR activity \[[@R22]\]. The individuals who carry heterozygous genetype (GA genetype) of *MTHFR* rs1801133 G\>A polymorphism have 70% of normal enzyme activity, however, those who carry homozygous genotype (AA genetype) have only 30% of normal enzyme activity \[[@R23]\]. A case-control study reported that rs1801133 AA genotype was associated an increased risk of GCA \[[@R24]\]. Another case-control study also found that *MTHFR* rs1801133 AA and GA genotypes were associated the increased risk of GCA \[[@R25]\]. These results were in accordance with our conclusions. In the future, more replicated study should be conducted to verify these primary findings.

*MTHFR* rs3753584 T\>C is situated in the intron region of *MTHFR* gene. There were only a few studies focusing on the association between *MTHFR* rs3753584 T\>C and cancer risk. A previous study found that there was an increased lung cancer risk in carriers of *MTHFR* rs3753584 CC genotype compared with carriers of rs3753584 TT genotype \[[@R26]\]. However, no association was found between ESCC risk and *MTHFR* rs3753584 T\>C polymorphism \[[@R11]\]. In addition, Wang *et al.* also reported that *MTHFR* rs3753584 T\>C was not associated with GCA risk \[[@R12]\]. The present study concluded that rs3753584 TC and TC/CC genotypes were related to a decreased EGJA risk in \<64 years subgroup. These apparent discrepancy findings may be due to the insufficient sample size. In the future, more studies with large sample size and detailed environmental factors are indispensable to explore the relationship between *MTHFR* rs3753584 T\>C and the risk of different cancers.

*MTHFR* rs4845882 G\>A polymorphism lies in a intron region and is almost complete linkage disequilibrium (LD) with *MTHFR* rs1801131 A\>C locus. Shen *et al.* found there was no significant relationship between *MTHFR* rs4845882 G\>A polymorphism and gastric cancer risk \[[@R27]\]. Additionally, the association between *MTHFR* rs4845882 G\>A and GCA risk was not concluded in a recent sutdy \[[@R12]\]. However, our study saw a decreased EGJA risk in the individuals carrying *MTHFR* rs4845882 AA genotype in male and \<64 years subgroups. *MTHFR* rs9651118 T\>C is situated in intron 2 and possesses low LD with rs1801133 G\>A (*r*^2^ \< 0.30). Fuctional annotation by HapReg demonstrated that *MTHFR* rs9651118 T\>C coincides with *MTHFR* enhancers or promoters, which may correspond to the regions of open chromatin \[[@R28]\]. Several studies implicated that *MTHFR* rs9651118 C allele was associated with a reduced risk of lung cancer and prostate cancer \[[@R28], [@R29]\]. In addition, *MTHFR* rs9651118 C allele was associated with a decreased risk of breast cancer \[[@R30]\]. Our results suggested that *MTHFR* rs9651118 TC genotype may reduce EGJA susceptibility in \<64 years subgroup, which were very similar to the findings of previous studies. In the future, these potential should be confirmed by functional studies.

In this case-control study, we constructed five *MTHFR* haplotypes to assess the potential inherited patterns of haplotype. We found that *MTHFR* G~rs1801133~T~rs3753584~G~rs4845882~A~rs4846048~C~rs9651118~, G~rs1801133~C~rs3753584~A~rs4845882~A~rs4846048~T~rs9651118~ and G~rs1801133~T~rs3753584~A~rs4845882~G~rs4846048~T~rs9651118~ haplotypes significantly decreased the risk of EGJA. To the best of our knowledge, we first explore the relationship of haplotypes in *MTHFR* rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms with EGJA susceptibility. We also found that *MTHFR* rs1801133 G and rs4845882 A alleles might be protective factors for haplotype to EGJA.

However, several limitations in our study should be presented. First, for the controls were recruited from the local hospitals, the selection bias of the study population should not be ignored. Second, the data of plasma folate level were not available, which may affect the association between *MTHFR* SNPs and EGJA susceptibility. Thirdly, for lack of cancer stage, disease progression and overall survival data, we did not consider the influence of *MTHFR* SNPs on progress and prognosis of EGJA. Last but not least, other environmental and genetic factors were not considered. Further studies are necessary to explore the effect of interactions between environment and gene factors on EGJA risk.

In conclusion, our study demonstrates that *MTHFR* rs1801133 G\>A may be associated with the increased risk of EGJA. Meanwhile, *MTHFR* rs3753584 T\>C, rs4845882 G\>A and rs9651118 T\>C polymorphisms decrease the risk of EGJA in Eastern Chinese Han population. The further case-control studies are needed to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

Study conducted at the Affiliated Union Hospital of Fujian Medical University, Fujian Medical University Cancer Hospital and the Affiliated People's Hospital of Jiangsu University was approved by the Ethics Committee of Fujian Medical University (Fuzhou, China) and Jiangsu University (Zhenjiang, China). Subjects were enrolled from three hospitals in Eastern China. Our study involved 2,740 study participants, comprising 1,063 histopathologically confirmed sporadic EGJA patients and 1,677 healthy normal controls. Among them, 280 EGJA patients and 840 controls were enrolled from Fujian Medical University Union Hospital and Cancer Hospital of Fujian Medical University from January 2014 to May 2016. In addition, 783 EGJA patients and 837 controls were enrolled from the Affiliated People's Hospital of Jiangsu University between January 2008 and November 2016. All EJGA patients were Siewert type II. The control group involved normal individuals who visited these hospitals for health check. The healthy normal controls were unrelated to the EGJA patients and were cancer-free individuals. Data of demographic details and risk factors was obtained using a structured questionnaire. The definition of 'ever smokers' were subjects who smoked at least one cigarette per day over 1 year \[[@R11]\], and 'ever drinkers' were subjects who drank no less than three times a week for more than 6 months \[[@R11]\]. The corresponding data are listed in Table [1](#T1){ref-type="table"}. The Ethical Committee of Fujian Medical University and Jiangsu University approved the study protocols (No. SQ2015-006-01 and No. 20150083, respectively).

Selection of SNPs {#s4_2}
-----------------

The *MTHFR* tagging SNPs (upstream and downstream of *MTHFR* gene extending 5 Kb, respectively) were selected from the database of CHB population using the HapMap Project (<http://hapmap.ncbi.nlm.nih.gov/index.html.en>) and Haploview 4.2 software. The major criterion were: (a) MAF ≥ 0.05 and call rate ≥ 95 %, (b) a HWE *P* ≥ 0.05, (c) a pairwise linkage disequilibrium (LD) *r*^*2*^ threshold of 0.8 between polymorphisms (*r*^2^ \> 0.8) \[[@R11], [@R31], [@R32]\]. Finally, five *MTHFR* tagging SNPs (rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C) were eligible and included in this case-control study to evaluate the effect of *MTHFR* polymorphisms with EGJA risk. The primary information of *MTHFR* tagging SNPs is presented in Table [2](#T2){ref-type="table"}.

DNA extraction and genotyping {#s4_3}
-----------------------------

Each participant donated 2ml blood sample which was stored in an EDTA-anticoagulated tube. We use the Promega Genomic DNA Purification Kit (Promega, Madison, USA) to extract the genomic DNA. SNPscan™ genotyping assay (Genesky Biotechologies Inc., Shanghai, China) \[[@R33], [@R34]\] was harnessed to determine the genotyping of *MTHFR* rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms. Briefly, 150ng DNA sample was denatured at 98°C for 5min. The ligation reaction was done in an ABI 2720 thermal cycler. We used a 48-plex fluorescence PCR reaction for each ligation product amplification. In an ABI 3730XL sequencer, PCR products were analyzed by capillary electrophoresis. The obtained raw data were conducted by GeneMapper 4.1 software (Applied Biosystems, USA). One hundred and ten DNA samples (4%) were randomly selected to reanalyze the genotypes by different laboratory technicians and the reproducibility was 100%.

Statistical analysis {#s4_4}
--------------------

Age of EGJA patients and controls was expressed as mean ± standard deviation. And a Student's t-test was harnessed to assess the difference for age. The Chi-square test (*χ*^2^) was used to compare age, sex, smoking, drinking and the genotypes distribution of *MTHFR* SNPs in patients and controls. We used multivariate logistic regression analysis to assess the risk of *MTHFR* rs1801133 G\>A, rs3753584 T\>C, rs4845882 G\>A, rs4846048 A\>G and rs9651118 T\>C polymorphisms and considered the confounders such as sex, age, smoking and drinking status. The crude/adjusted ORs and 95% CIs were calculated using the SAS software (Version 9.4; SAS Institute Inc., Cary, NC, USA). A *P* \< 0.05 (two sided) was considered as statistical significance. In this study, multiple comparisons were conducted by Bonferroni correction \[[@R35]\]. We used a SHESIS software (<http://analysis.bio-x.cn/myAnalysis.php>) \[[@R17]\] to construct *MTHFR* haplotypes.
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